Avecho Biotechnology (ASX: AVE) Webcast Replay
8th December, 2021
Avecho Biotechnology (ASX: AVE) is a pharma innovator offering a world-first drug delivery platform used in the projected US$55 billion cannabidiol market.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Dr Paul Gavin, provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 8th December 2021 at 12pm (AEDT).
Join the next The Insider: Meet the CEOs webcast
FEATURED SPEAKER
Dr Paul Gavin
CEO - Avecho Biotechnology Limited (ASX: AVE)
Avecho develops and commercialises innovative human and animal health products using its proprietary drug delivery system Tocopheryl Phosphate Mixture (TPM). TPM is the world’s first and only drug delivery platform produced using a patented process that combines two different forms of tocopheryl phosphate, an enhanced form of vitamin E. The platform increases the bioavailability of drugs it delivers by 4-40 times, thereby increasing the effectiveness of the drug and reducing dosage. Avecho operates in, among others, the global cannabidiol market, which is expected to grow to US$55 billion by 2028.
